NCT06451198View on ClinicalTrials.gov

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

2,846

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Coronary Artery Disease
Interventions
DRUG

Indobufen

Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.

DRUG

Aspirin

Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.

DRUG

Ticagrelor

All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06451198 - IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter